RxDoctor Payments Data

Anthony Buscaglia, MD

Pulmonary Disease · Hamburg, NYNPI 1265579536

Payments from drug & device makers

$4,257in general payments, 2019–2025

Across 240 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$802
  • AstraZeneca$560
  • Grifols USA, LLC$219
  • Sanofi$213
  • Amgen$207
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,257 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$27,701
Medicare patients
165
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate19$363,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter247$289,578
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr113$88,253
Spiriva RespimatTiotropium Bromide93$85,073
Breo ElliptaFluticasone/Vilanterol102$71,295
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$45,312
Spiriva HandihalerTiotropium Bromide39$40,567
SymbicortBudesonide/Formoterol Fumarate55$31,931
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$29,281
Pirfenidone12$27,418
Incruse ElliptaUmeclidinium Bromide27$16,057
Fluticasone-SalmeterolFluticasone Propion/Salmeterol60$15,945
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$10,985
Albuterol Sulfate HfaAlbuterol Sulfate233$10,686
Wixela InhubFluticasone Propion/Salmeterol11$3,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$802$493,833155 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,018$465,183489 claims
AstraZenecaSymbicort, Breztri Aerosphere$560$61,21392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →